Abstract: A trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different, and respectively represent hydrogen, C.sub.1-10 alkyl, C.sub.2-5 alkanoyl, formyl, C.sub.1-4 alkoxy-carbonyl, amidino, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylcarbonyl, phenyl, phenylalkyl, benzoyl, naphthoyl, phenylalkoxycarbonyl, benzylidene, pyridylcarbonyl, piperidyl, pyrrolidylidene or piperidylidene which may be optionally substituted on the ring or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom form 5 to 6-membered cycle which may have oxygen atom, sulfur atom or optionally substituted nitrogen atom in the cycle, or together with the adjacent nitrogen atom form phthalimido, R.sup.3 represents hydrogen or C.sub.1-4 alkyl, R.sup.4 represents hydrogen or C.sub.1-4 alkyl, R.sup.5 represents hydrogen, hydroxy, C.sub.1-4 alkyl or phenylalkoxy. R.sup.6 represents hydrogen or C.sub.1-4 alkyl, A represents single bond, C.sub.

Abstract: Isoxazole derivatives represented by the formula ##STR1## wherein Ar, R.sup.1, R.sup.2 and Am are as defined in the specification, or salts thereof. These compounds are useful as drugs such as psychotropic agent, antiemetic agent, etc.

Abstract: Morpholine compounds of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and pharmaceutically acceptable acid addition salts thereof, have strong inhibitory activities on peptic ulcer, gastric motility and gastric secretion but have very weak acetylcholine antagonistic activity.

Abstract: Substituted phenylalkanoic acids and derivatives thereof of the formula: ##SPC1##Wherein each of R.sup.1 and R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; each of X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; Y is COOH, COOR (wherein R is an alkyl group having 1 to 4 carbon atoms), CONH.sub.2, CSNH.sub.2, CN or COZ--A--N(R.sup.3)(R.sup.4) (wherein Z is an oxygen atom or an imino group, A is an alkylene group having 2 to 4 carbon atoms and each of R.sup.3 and R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R.sup.3 and R.sup.

Abstract: 1-[Methylated piperidino (and pyrrolidin-1-yl)]-3-(substituted phenoxy)-2-propanols of the formula: ##SPC1##Wherein R is a 2-thienylmethyl group, a 2-pyridylmethyl group, a 2-pyridyl group, a tetrahydrofurfuryloxy group, a furfuryloxy group, a 2-thienylmethoxy group, a 2-pyridyloxy group or a group of the formula R.sup.5 --X--A--O-- wherein R.sup.5 is a lower alkyl group, X is --O--, --S-- or --SO.sub.2 --, and A is a lower alkylene group or a --CH.sub.2 --C.ident.C--CH.sub.2 -- group, R.sup.1 is a hydrogen atom, a lower alkyl group or a halogen atom, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a methyl group, and n is zero or 1, and pharmaceutically acceptable acid addition and quarternary ammonium salts thereof are disclosed. They exhibit antiarrhythmic action, local anaesthetic action, analgesic action and gastric juice secretion inhibiting action.